8-K Announcements
6Material company update
Feb 26, 2026·SEC
Material company update
Jan 20, 2026·SEC
Material company update
Jan 12, 2026·SEC
Novavax, Inc.(NVAX)Earnings, Financials & Key Ratios
NVAX•NASDAQ
$9.36
$1.54B mkt cap·3.6× P/E·Price updated May 6, 2026
AboutNovavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.Show more
- Revenue$1.12B+64.7%
- EBITDA$453M+325.9%
- Net Income$440M+334.8%
- EPS (Diluted)2.58+309.8%
- Gross Margin93.5%+33.0%
- EBITDA Margin40.3%+237.2%
- Operating Margin40.3%+210.4%
- Net Margin39.19%+242.6%
NVAX Key Insights
Novavax, Inc. (NVAX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 118.8%
✗Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 13.7% in last year
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
NVAX Price & Volume
Novavax, Inc. (NVAX) stock price & volume — 10-year historical chart
Loading chart...
NVAX Growth Metrics
Novavax, Inc. (NVAX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years40.97%
5 Years118.83%
3 Years-11.1%
TTM64.69%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM334.83%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM293.99%
Return on Capital
10 Years-113.88%
5 Years-159.88%
3 Years-118.62%
Last Year80.67%
NVAX Recent Earnings
Novavax, Inc. (NVAX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 5/12 qtrs (42%)
Q1 2026Latest
Feb 26, 2026EPS
$0.11
Est $0.66
+116.7%
Revenue
$147M
Est $90M
+63.8%
Q4 2025
Nov 6, 2025EPS
$0.62
Est $1.08
+42.6%
Revenue
$70M
Est $90M
-22.0%
Q3 2025
Aug 6, 2025EPS
$0.62
Est $0.07
+985.7%
Revenue
$239M
Est $56M
+330.1%
Q2 2025
May 8, 2025EPS
$2.93
Est $0.71
+312.7%
Revenue
$667M
Est $344M
+93.9%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 26, 2026 | $0.11vs $0.66+116.7% | $147Mvs $90M+63.8% |
| Q4 2025 | Nov 6, 2025 | $0.62vs $1.08+42.6% | $70Mvs $90M-22.0% |
| Q3 2025 | Aug 6, 2025 | $0.62vs $0.07+985.7% | $239Mvs $56M+330.1% |
| Q2 2025 | May 8, 2025 | $2.93vs $0.71+312.7% | $667Mvs $344M+93.9% |
Based on last 12 quarters of dataView full earnings history →
NVAX Peer Comparison
Novavax, Inc. (NVAX) competitors in Vaccines and Infectious Disease — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 MRNA | 19.35B | 48.79 | -6.72 | -39.23% | -143.55% | -36.73% | 0.22 | |
 BNTX | 23.94B | 95.26 | -18.00 | 0.2% | -39.6% | -6.03% | 1.32% | 0.01 |
 PFE | 150.77B | 26.51 | 19.49 | -1.65% | 11.83% | 8.34% | 6.02% | 0.78 |
 SNY | 105.71B | 43.77 | 18.37 | 5.49% | 16.72% | 10.78% | 9.87% | 0.30 |
 GSK | 101.62B | 50.53 | 6.69 | 4.11% | 19.19% | 31.48% | 7.79% | 1.11 |
 DVAX | 1.82B | 15.50 | 77.50 | 19.36% | -13.13% | -8.13% | 3.31% | 0.43 |
 VALN | 470M | 5.41 | -27.12 | 10.32% | -56.78% | -58.93% | 1.19 | |
 IBRX | 8.25B | 8.38 | -13.52 | 22.71% | -422.28% |
Compare NVAX vs Peers
Novavax, Inc. (NVAX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NVAX Income Statement
Novavax, Inc. (NVAX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 31.18M | 34.29M | 18.66M | 22.39M | 197.58M | 1.6B | 556.38M | 682.16M | 1.12B |
| Revenue Growth % | 103.06% | 9.98% | -45.57% | 19.97% | 782.53% | 709.26% | -65.2% | 22.61% | 64.69% |
| Cost of Goods Sold | 0 | 0 | 113.84M | 0 | 0 | 902.64M | 343.77M | 202.74M | 73.04M |
| COGS % of Revenue | - | - | 610.02% | - | - | 56.45% | 61.79% | 29.72% | 6.5% |
| Gross Profit | 31.18M▲ 0% | 34.29M▲ 10.0% | -95.18M▼ 377.6% | 22.39M▲ 123.5% | 197.58M▲ 782.5% | 696.31M▲ 252.4% | 212.61M▼ 69.5% | 479.42M▲ 125.5% | 1.05B▲ 119.1% |
| Gross Margin % | 100% | 100% | -510.02% | 100% | 100% | 43.55% | 38.21% | 70.28% | 93.5% |
| Gross Profit Growth % | 114.01% | 9.98% | -377.59% | 123.52% | 782.53% | 252.42% | -69.47% | 125.49% | 119.1% |
| Operating Expenses | 202.89M | 208.21M | 148.26M | 439.11M | 1.88B | 1.34B | 779.13M | 728.35M | 499.8M |
| OpEx % of Revenue | 650.78% | 607.23% | 794.44% | 1961.35% | 953.61% | 83.87% | 140.03% | 106.77% | 44.49% |
| Selling, General & Admin | 34.45M | 34.41M | 34.42M | 145.29M | 298.36M | 488.69M | 468.95M | 337.19M | 157.48M |
| SG&A % of Revenue | 110.5% | 100.35% | 184.42% | 648.96% | 151.01% | 30.56% | 84.28% | 49.43% | 14.02% |
| Research & Development | 168.44M | 173.8M | 113.84M | 747.03M | 2.53B | 1.24B | 737.5M | 391.17M | 342.32M |
| R&D % of Revenue | 540.27% | 506.87% | 610.02% | 3336.73% | 1282.77% | 77.26% | 132.55% | 57.34% | 30.47% |
| Other Operating Expenses | 67K | 108K | -13K | -453.21M | -948.71M | -382.92M | -427.32M | 0 | 0 |
| Operating Income | -171.71M▲ 0% | -173.92M▼ 1.3% | -120.58M▲ 30.7% | -416.72M▼ 245.6% | -1.69B▼ 304.7% | -644.74M▲ 61.8% | -566.51M▲ 12.1% | -248.93M▲ 56.1% | 452.8M▲ 281.9% |
| Operating Margin % | -550.78% | -507.23% | -646.13% | -1861.35% | -853.61% | -40.32% | -101.82% | -36.49% | 40.3% |
| Operating Income Growth % | 36.19% | -1.29% | 30.67% | -245.59% | -304.73% | 61.77% | 12.13% | 56.06% | 281.9% |
| EBITDA | -161.89M | -165.76M | -114.78M | -411.83M | -1.67B | -615.68M | -525.29M | -200.44M | 452.8M |
| EBITDA Margin % | -519.29% | -483.43% | -615.05% | -1839.53% | -847.2% | -38.51% | -94.41% | -29.38% | 40.3% |
| EBITDA Growth % | 37.88% | -2.39% | 30.75% | -258.8% | -306.45% | 63.22% | 14.68% | 61.84% | 325.91% |
| D&A (Non-Cash Add-back) | 9.82M | 8.16M | 5.8M | 4.88M | 12.66M | 29.05M | 41.23M | 48.5M | 0 |
| EBIT | -169.7M | -172.56M | -119.08M | -403.11M | -1.69B | -633.77M | -528.62M | -156.54M | 0 |
| Net Interest Income | -14.07M | -13.61M | -12.1M | -15.14M | -21.13M | -19.88M | -14.42M | -20.07M | 0 |
| Interest Income | 0 | 0 | 1.51M | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 14.07M | 12.19M | 13.61M | 15.14M | 21.13M | 19.88M | 14.42M | 20.07M | -22.55M |
| Other Income/Expense | -12.06M | -10.83M | -12.11M | -1.54M | -27.96M | -8.91M | 23.48M | 72.32M | -10.63M |
| Pretax Income | -183.77M▲ 0% | -184.75M▼ 0.5% | -132.69M▲ 28.2% | -418.26M▼ 215.2% | -1.71B▼ 309.9% | -653.65M▲ 61.9% | -543.03M▲ 16.9% | -176.62M▲ 67.5% | 442.17M▲ 350.4% |
| Pretax Margin % | -589.46% | -538.81% | -711.04% | -1868.23% | -867.76% | -40.88% | -97.6% | -25.89% | 39.36% |
| Income Tax | 0 | 1.36M | 0 | 0 | 29.21M | 4.29M | 2.03M | 10.88M | -1.86M |
| Effective Tax Rate % | 0% | -0.74% | 0% | 0% | -1.7% | -0.66% | -0.37% | -6.16% | -0.42% |
| Net Income | -183.77M▲ 0% | -184.75M▼ 0.5% | -130.1M▲ 29.6% | -418.26M▼ 221.5% | -1.74B▼ 316.9% | -657.94M▲ 62.3% | -545.06M▲ 17.2% | -187.5M▲ 65.6% | 440.3M▲ 334.8% |
| Net Margin % | -589.46% | -538.81% | -697.15% | -1868.23% | -882.55% | -41.15% | -97.97% | -27.49% | 39.19% |
| Net Income Growth % | 34.36% | -0.53% | 29.58% | -221.49% | -316.91% | 62.27% | 17.16% | 65.6% | 334.83% |
| Net Income (Continuing) | -183.77M | -184.75M | -132.69M | -418.26M | -1.74B | -657.94M | -545.06M | -187.5M | 440.3M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -12.56▲ 0% | -9.99▲ 20.5% | -5.40▲ 45.9% | -7.43▼ 37.6% | -23.44▼ 215.5% | -8.42▲ 64.1% | -5.41▲ 35.7% | -1.23▲ 77.3% | 2.58▲ 309.8% |
| EPS Growth % | 39.27% | 20.46% | 45.95% | -37.59% | -215.48% | 64.08% | 35.75% | 77.26% | 309.76% |
| EPS (Basic) | -12.56 | -9.99 | -5.40 | -7.43 | -23.44 | -8.42 | -5.41 | -1.23 | 2.72 |
| Diluted Shares Outstanding | 14.63M | 18.49M | 24.1M | 57.55M | 74.4M | 78.18M | 100.77M | 152.19M | 173.1M |
| Basic Shares Outstanding | 14.63M | 18.49M | 24.1M | 57.55M | 74.4M | 78.18M | 100.77M | 152.19M | 161.99M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
NVAX Balance Sheet
Novavax, Inc. (NVAX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 203.31M | 119.28M | 97.25M | 1.25B | 2.16B | 1.7B | 1.14B | 1.13B | 978.28M |
| Cash & Short-Term Investments | 106.31M | 70.15M | 78.82M | 711.05M | 1.52B | 1.34B | 568.5M | 923.12M | 735.08M |
| Cash Only | 106.31M | 70.15M | 78.82M | 553.4M | 1.52B | 1.34B | 568.5M | 530.23M | 240.63M |
| Short-Term Investments | 0 | 0 | 0 | 157.65M | 0 | 0 | 0 | 392.89M | 494.45M |
| Accounts Receivable | 0 | 0 | 7.5M | 262.01M | 454.99M | 82.38M | 297.24M | 108.28M | 106.45M |
| Days Sales Outstanding | - | - | 146.69 | 4.27K | 840.53 | 18.8 | 195 | 57.94 | 34.58 |
| Inventory | 13.09M | 11.97M | 0 | 0 | 0 | 36.68M | 41.7M | 8.75M | 11.54M |
| Days Inventory Outstanding | - | - | - | - | - | 14.83 | 44.27 | 15.75 | 57.69 |
| Other Current Assets | 19.84M | 3.19M | 7.32M | 103.54M | 56.11M | 86.68M | 166.15M | 32.51M | 125.2M |
| Total Non-Current Assets | 99.18M | 88.7M | 75.71M | 334.28M | 421.63M | 555.29M | 653.6M | 431.48M | 198.24M |
| Property, Plant & Equipment | 35.99M | 28.43M | 11.45M | 179.95M | 228.7M | 400.49M | 490.99M | 300M | 67.7M |
| Fixed Asset Turnover | 0.87x | 1.21x | 1.63x | 0.12x | 0.86x | 3.99x | 1.13x | 2.27x | 16.60x |
| Goodwill | 53.56M | 51.97M | 51.15M | 135.38M | 131.48M | 126.33M | 127.45M | 107.48M | 113.46M |
| Intangible Assets | 7.87M | 6.54M | 5.58M | 5.72M | 4.77M | 0 | 0 | 0 | 0 |
| Long-Term Investments | 890K | 958K | 410K | 0 | 1.65M | 1.66M | 0 | 0 | 0 |
| Other Non-Current Assets | 1.76M | 1.77M | 7.53M | 13.22M | 56.69M | 28.47M | 35.16M | 24M | 17.08M |
| Total Assets | 302.49M▲ 0% | 207.98M▼ 31.2% | 172.96M▼ 16.8% | 1.58B▲ 815.0% | 2.58B▲ 62.8% | 2.26B▼ 12.3% | 1.8B▼ 20.4% | 1.56B▼ 13.2% | 1.18B▼ 24.6% |
| Asset Turnover | 0.10x | 0.16x | 0.11x | 0.01x | 0.08x | 0.71x | 0.31x | 0.44x | 0.95x |
| Asset Growth % | -23.28% | -31.25% | -16.84% | 814.96% | 62.83% | -12.34% | -20.42% | -13.19% | -24.6% |
| Total Current Liabilities | 73.67M | 45.54M | 25.8M | 579.67M | 2.39B | 2.46B | 1.64B | 1.15B | 459.95M |
| Accounts Payable | 5.61M | 9.3M | 2.91M | 54.33M | 127.05M | 216.52M | 132.61M | 41.58M | 24.58M |
| Days Payables Outstanding | - | - | 9.33 | - | - | 87.55 | 140.8 | 74.86 | 122.82 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 324.88M | 0 | 0 | 2.51M |
| Deferred Revenue (Current) | 25.63M | 10.01M | 1.68M | 273.23M | 1.42B | 370.14M | 241.31M | 675.07M | 140.05M |
| Other Current Liabilities | 31.25M | 16.6M | 12.44M | 29.61M | 74.48M | 982.62M | 917.36M | 279.95M | 317.39M |
| Current Ratio | 2.76x | 2.62x | 3.77x | 2.15x | 0.90x | 0.69x | 0.70x | 0.98x | 2.13x |
| Quick Ratio | 2.58x | 2.36x | 3.77x | 2.15x | 0.90x | 0.68x | 0.67x | 0.97x | 2.10x |
| Cash Conversion Cycle | - | - | - | - | - | -53.92 | 98.47 | -1.17 | -30.55 |
| Total Non-Current Liabilities | 330.55M | 330.37M | 333.18M | 375.6M | 538.11M | 432.81M | 879.28M | 1.03B | 844.32M |
| Long-Term Debt | 317.76M | 319.19M | 320.61M | 322.04M | 323.46M | 166.47M | 168.02M | 169.68M | 246.3M |
| Capital Lease Obligations | 0 | 0 | 0 | 40.08M | 0 | 31.24M | 55.92M | 53.73M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 10.29M | 8.69M | 10.07M | 13.48M | 42.12M | 55.7M | 33.13M | 359.61M | 598.01M |
| Total Liabilities | 404.23M | 375.91M | 358.97M | 955.27M | 2.93B | 2.89B | 2.51B | 2.18B | 1.3B |
| Total Debt | 317.76M | 319.19M | 321.87M | 467.98M | 453.99M | 549.78M | 229.08M | 230.42M | 248.81M |
| Net Debt | 211.46M | 249.03M | 243.05M | -85.42M | -1.06B | -787.1M | -339.42M | -299.81M | 8.18M |
| Debt / Equity | - | - | - | 0.75x | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | 0.55x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | 0.02x |
| Interest Coverage | -12.20x | -14.27x | -8.86x | -27.52x | -79.83x | -32.43x | -39.30x | -12.40x | - |
| Total Equity | -101.73M▲ 0% | -167.94M▼ 65.1% | -186.02M▼ 10.8% | 627.21M▲ 437.2% | -351.67M▼ 156.1% | -634.08M▼ 80.3% | -716.93M▼ 13.1% | -623.84M▲ 13.0% | -127.75M▲ 79.5% |
| Equity Growth % | -1734.33% | -65.08% | -10.77% | 437.18% | -156.07% | -80.3% | -13.07% | 12.98% | 79.52% |
| Book Value per Share | -6.95 | -9.08 | -7.72 | 10.90 | -4.73 | -8.11 | -7.11 | -4.10 | -0.74 |
| Total Shareholders' Equity | -101.73M | -167.94M | -186.02M | 627.21M | -351.67M | -634.08M | -716.93M | -623.84M | -127.75M |
| Common Stock | 3.24M | 3.85M | 324K | 714K | 764K | 868K | 1.41M | 1.62M | 1.65M |
| Retained Earnings | -1.11B | -1.3B | -1.43B | -1.87B | -3.62B | -4.28B | -4.82B | -5.01B | -4.57B |
| Treasury Stock | -2.45M | -2.45M | -2.58M | -41.81M | -85.1M | -90.66M | -92.27M | -95.85M | 0 |
| Accumulated OCI | -8.62M | -11.19M | -12.51M | 7.02M | -1.35M | -6.38M | 2.72M | -22.56M | 2.01M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NVAX Cash Flow Statement
Novavax, Inc. (NVAX) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -138.7M | -184.82M | -136.62M | -42.54M | 322.95M | -415.94M | -713.97M | -87.26M | -244.63M |
| Operating CF Margin % | -444.88% | -539.04% | -732.09% | -190.02% | 163.45% | -26.01% | -128.32% | -12.79% | -21.77% |
| Operating CF Growth % | 45.71% | -33.26% | 26.08% | 68.86% | 859.14% | -228.79% | -71.65% | 87.78% | -180.34% |
| Net Income | -183.77M | -184.75M | -132.69M | -418.26M | -1.74B | -657.94M | -545.06M | -187.5M | 440.3M |
| Depreciation & Amortization | 9.82M | 8.16M | 5.68M | 4.88M | 12.66M | 29.05M | 41.23M | 48.5M | 27.61M |
| Stock-Based Compensation | 19.81M | 18.31M | 17.05M | 128.03M | 183.63M | 130.3M | 85.36M | 48.15M | 36.02M |
| Deferred Taxes | 269K | -55K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 6.07M | -5.35M | -2.63M | 230.78M | 136.79M | 443.8M | 81.35M | -44.89M | -748.57M |
| Working Capital Changes | 9.11M | -21.14M | -24.02M | 12.02M | 1.73B | -361.15M | -376.84M | 48.48M | 0 |
| Change in Receivables | 0 | 1.21M | -4.2M | -422.69M | -192.26M | 249.17M | -274.44M | 354.09M | 61.04M |
| Change in Inventory | 0 | 0 | 0 | 0 | -600.33M | -477.8M | -74.46M | 12.91M | -3.24M |
| Change in Payables | 5.19M | -6.74M | 0 | 163.16M | 600.33M | 913.4M | -378.81M | -385.63M | -322.57M |
| Cash from Investing | 35.97M | 28.6M | 38.49M | -377.78M | 100.15M | -92.98M | -58.81M | -204.04M | -78.27M |
| Capital Expenditures | -4.19M | -1.37M | -1.86M | -54.62M | -57.49M | -92.98M | -58.81M | -14.64M | -5.56M |
| CapEx % of Revenue | 13.44% | 4% | 9.95% | 243.98% | 29.09% | 5.82% | 10.57% | 2.15% | 0.49% |
| Acquisitions | 4.19M | 1.37M | 0 | -165.52M | 57.49M | 0 | 0 | 192.64M | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | -4.19M | -1.37M | 18.33M | 0 | -57.49M | 0 | 0 | 0 | 18.82M |
| Cash from Financing | 64.54M | 102.81M | 98.38M | 984.76M | 461.71M | 324.99M | 4.47M | 260.58M | 27.74M |
| Debt Issued (Net) | -37K | 0 | 0 | -96.06M | -127.91M | 81.66M | -352.35M | -3.99M | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 1.15M | 2.75M | 992K | 5.38M | 24.76M | -5.9M | -3.59M | 1.3M | 27.74M |
| Net Change in Cash | -38.05M▲ 0% | -53.47M▼ 40.5% | 221K▲ 100.4% | 566.56M▲ 256261.1% | 879.52M▲ 55.2% | -179.41M▼ 120.4% | -765.03M▼ 326.4% | -38.52M▲ 95.0% | -289.24M▼ 650.9% |
| Free Cash Flow | -142.88M▲ 0% | -186.2M▼ 30.3% | -138.48M▲ 25.6% | -97.16M▲ 29.8% | 265.46M▲ 373.2% | -508.92M▼ 291.7% | -772.77M▼ 51.8% | -100.32M▲ 87.0% | -250.19M▼ 149.4% |
| FCF Margin % | -458.32% | -543.04% | -742.04% | -434% | 134.35% | -31.83% | -138.89% | -14.71% | -22.27% |
| FCF Growth % | 47.79% | -30.31% | 25.63% | 29.84% | 373.21% | -291.71% | -51.85% | 87.02% | -149.4% |
| FCF per Share | -9.76 | -10.07 | -5.75 | -1.69 | 3.57 | -6.51 | -7.67 | -0.66 | -1.45 |
| FCF Conversion (FCF/Net Income) | 0.75x | 1.00x | 1.05x | 0.10x | -0.19x | 0.63x | 1.31x | 0.47x | -0.56x |
| Interest Paid | 0 | 0 | 12.19M | 13.71M | 19.43M | 18.04M | 17.35M | 17.57M | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 12.61M | 17.98M | 190K | 949K | 0 |
NVAX Key Ratios
Novavax, Inc. (NVAX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -195.01% | - | - | - | -189.6% | -1265.72% | - | - | - | - |
| Return on Invested Capital (ROIC) | -110.17% | -93.27% | -136.71% | -130.94% | -104.38% | - | - | - | - | - |
| Gross Margin | -1449.79% | 100% | 100% | -510.02% | 100% | 100% | 43.55% | 38.21% | 70.28% | 93.5% |
| Net Margin | -1823.53% | -589.46% | -538.81% | -697.15% | -1868.23% | -882.55% | -41.15% | -97.97% | -27.49% | 39.19% |
| Debt / Equity | - | - | - | - | 0.75x | - | - | - | - | - |
| Interest Coverage | -20.76x | -12.20x | -14.27x | -8.86x | -27.52x | -79.83x | -32.43x | -39.30x | -12.40x | - |
| FCF Conversion | 0.91x | 0.75x | 1.00x | 1.05x | 0.10x | -0.19x | 0.63x | 1.31x | 0.47x | -0.56x |
| Revenue Growth | -57.65% | 103.06% | 9.98% | -45.57% | 19.97% | 782.53% | 709.26% | -65.2% | 22.61% | 64.69% |
NVAX SEC Filings & Documents
Novavax, Inc. (NVAX) SEC filings — annual & quarterly reports (10-K, 10-Q)
NVAX Frequently Asked Questions
Novavax, Inc. (NVAX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Novavax, Inc. (NVAX) reported $1.12B in revenue for fiscal year 2025. This represents a 1123379% increase from $0.1M in 1996.
Novavax, Inc. (NVAX) grew revenue by 64.7% over the past year. This is strong growth.
Yes, Novavax, Inc. (NVAX) is profitable, generating $440.3M in net income for fiscal year 2025 (39.2% net margin).
Dividend & Returns
Novavax, Inc. (NVAX) had negative free cash flow of $250.6M in fiscal year 2025, likely due to heavy capital investments.
Explore More NVAX
Novavax, Inc. (NVAX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates